Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab plus total skin electron beam therapy in stage IB-IIB cutaneous T-cell lymphoma
2019-004566-17Phase 2Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), Sézary syndrome (SS) and mycosis fungoides (MF), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 48 weeks (PFSR-48). Started May 2021; status: active.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)Sézary syndrome (SS)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2019-004566-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004566-17.